Jonathan I. Lieber, Chief Financial Officer of Rallybio Corp, filed a Form 4 on November 3, 2026, disclosing the exercise of stock options and acquisition of common stock on November 2, 2026.

Key Highlights

  • Reporting person: Jonathan I. Lieber, Chief Financial Officer of Rallybio Corp (NASDAQ:RLYB)
  • Transaction: 7,124 shares of common stock acquired via option exercise (transaction code M) on November 2, 2026, at a price of $14.88 per share
  • Resulting ownership: Lieber directly held 44,139 shares of common stock following the transaction
  • Derivative security: The corresponding option (right to buy) with an exercise price of $14.88 and expiration date of February 15, 2034, was fully exercised, leaving zero options remaining
  • Accelerated vesting: According to the filing, on October 26, 2026, vesting of the option was accelerated in full under the company's 2021 Equity Incentive Plan

Rallybio CFO Option Exercise: Transaction Details and Background

According to the filing, Jonathan I. Lieber, serving as Chief Financial Officer of Rallybio Corp, exercised an option to acquire 7,124 shares of common stock on November 2, 2026. The transaction was recorded under transaction code M, indicating the exercise of an in-the-money or at-the-money derivative security. The exercise price was $14.88 per share. Following the transaction, Lieber directly held 44,139 shares of Rallybio common stock, as reported in Table I of the filing.

The filing notes in its explanation of responses that the option was granted under Rallybio's 2021 Equity Incentive Plan. The filing states: "On October 26, 2026, the vesting of the option was accelerated in full, and the option became fully vested and exercisable as of that date." The option, which carried an expiration date of February 15, 2034, was fully exercised in this transaction, with zero derivative securities remaining in Lieber's holdings afterward, as reflected in Table II of the filing.

The Form 4 was filed by one reporting person and covers the earliest transaction date of November 2, 2026. Lieber's address is listed as c/o Rallybio Corporation, PO Box 325, East Berlin, Connecticut 06023. The filing was signed by Jonathan Lieber and dated November 3, 2026.

What Was Disclosed

The filing disclosed a single option exercise by Rallybio's CFO on November 2, 2026, covering 7,124 shares at $14.88, with vesting having been accelerated on October 26, 2026. Following the transaction, Lieber directly held 44,139 shares of common stock.